e-Therapeutics plc Provides Update on Progress of ETS2101 Cancer Trials
Published: Dec 18, 2012
OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics plc (AIM: ETX) today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013. The phase I studies are designed to select appropriate doses for further trials, assess the safety and pharmacokinetics of ETS2101 and record any initial signs of anti-cancer activity. They have a dose-escalating design in which successive cohorts of patients receive higher doses of drug until a maximum tolerated dose is identified. To date 12 patients – two cohorts of three patients in each trial – have been treated. Some patients have completed multiple cycles of treatment with ETS2101; a number continue to be treated having received up to 11 weekly doses.